Lipid-lowering therapies and cardiovascular risk-stratification strategies in adults with type 1 diabetes
Lipid-lowering therapies and cardiovascular risk-stratificat... : Current Opinion in
Endocrinology, Diabetes and Obesity Lipid-lowering therapies and cardiovascular risk-stratification …
Endocrinology, Diabetes and Obesity Lipid-lowering therapies and cardiovascular risk-stratification …
Therapeutic roles of PPARα activation in ocular ischemic diseases
Ocular ischemia is one of the leading causes of blindness. It is related to various ocular
diseases and disorders, including age-related macular degeneration, diabetic retinopathy …
diseases and disorders, including age-related macular degeneration, diabetic retinopathy …
Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: a …
NH Kim, J Choi, YH Kim, H Lee, SG Kim - Diabetes & Metabolism, 2023 - Elsevier
Aim This study aimed to determine the association between fenofibrate added to statin
therapy and diabetic retinopathy progression. Methods In this propensity-matched study …
therapy and diabetic retinopathy progression. Methods In this propensity-matched study …
Effect of Fenofibrate on Progression of Diabetic Retinopathy
D Preiss, J Logue, E Sammons, M Zayed… - NEJM …, 2024 - evidence.nejm.org
Background Findings from cardiovascular outcome trials suggest that fenofibrate therapy
may reduce the progression of diabetic retinopathy. Methods We recruited and followed …
may reduce the progression of diabetic retinopathy. Methods We recruited and followed …
Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2
EA Brinton, VP Pulipati - Lipoproteins in Diabetes Mellitus, 2023 - Springer
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and
mortality in developed countries, especially among patients with diabetes mellitus type 2 …
mortality in developed countries, especially among patients with diabetes mellitus type 2 …
Preventing diabetes complications
S Templer, S Abdo, T Wong - Internal Medicine Journal, 2024 - Wiley Online Library
The key aim of diabetes management is to prevent complications, which are a major cause
of morbidity and mortality. At an individual level, people with diabetes are less likely than …
of morbidity and mortality. At an individual level, people with diabetes are less likely than …
[HTML][HTML] Underprescription of Fibrate Among Patients With Diabetic Retinopathy in Perak, Malaysia
J Jamaluddin, MAM Kamel - Cureus, 2024 - ncbi.nlm.nih.gov
Objectives Diabetic retinopathy (DR) is a major cause of blindness and its prevalence is
increasing. Fibrate, specifically fenofibrate, has been shown to be efficacious in reducing the …
increasing. Fibrate, specifically fenofibrate, has been shown to be efficacious in reducing the …
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
A Bobik, N Cohen, AJ Jenkins, T Kyaw… - Lipoproteins in Diabetes …, 2023 - Springer
Dyslipidemia manifesting as elevated LDL cholesterol and triglycerides, and low HDL
cholesterol is the major hallmark of the factors leading to the development of …
cholesterol is the major hallmark of the factors leading to the development of …
Fibrates: past history or renaissance?
R Elkeles - British Journal of Diabetes, 2023 - bjd-abcd.com
Fibrates: past history or renaissance? Page 1 REVIEW Volume 23 Issue 2 / December 2023 65
Fibrates: past history or renaissance? ROBERT ELKELES Abstract Fibrates have been in use to …
Fibrates: past history or renaissance? ROBERT ELKELES Abstract Fibrates have been in use to …
Leczenie dyslipidemii u chorych z cukrzycą typu 2
P Gajda, G Dzida - Medycyna Faktów, 2023 - journalsmededu.pl
Terapia dyslipidemii jest jednym z głównych elementów leczenia cukrzycy typu 2–
osiągnięcie docelowych stężeń cholesterolu LDL, nie-HDL oraz triglicerydów pozwala na …
osiągnięcie docelowych stężeń cholesterolu LDL, nie-HDL oraz triglicerydów pozwala na …